CY1108686T1 - (20s)-1 α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομοπρεγνακαλσιφερολη και οι χρησεις της - Google Patents

(20s)-1 α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομοπρεγνακαλσιφερολη και οι χρησεις της

Info

Publication number
CY1108686T1
CY1108686T1 CY20091100032T CY091100032T CY1108686T1 CY 1108686 T1 CY1108686 T1 CY 1108686T1 CY 20091100032 T CY20091100032 T CY 20091100032T CY 091100032 T CY091100032 T CY 091100032T CY 1108686 T1 CY1108686 T1 CY 1108686T1
Authority
CY
Cyprus
Prior art keywords
skin
compound
methylene
hydroxy
well
Prior art date
Application number
CY20091100032T
Other languages
English (en)
Inventor
Hector F Deluca
Lori A Plum
Margaret Clagett-Dame
James B Thoden
Hazel M Holden
Sumithra Gowlugari
Pawel Grzywacz
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/078,204 external-priority patent/US6627622B2/en
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CY1108686T1 publication Critical patent/CY1108686T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει την (20S)-1α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομο-πρεγνακαλσιφερόλη, φαρμακευτικές χρήσεις της και μία μέθοδο καθαρισμού αυτής της ενώσεως για τη λήψη της σε κρυσταλλική μορφή. Η ένωση αυτή εμφανίζει έντονη δράση στην ανακοπή του πολλαπλασιασμού αδιαφοροποίητων κυττάρων και στην επαγωγή της διαφοροποιήσεως τους προς μονοκύτταρα δικαιολογώντας έτσι τη χρήση της ως αντικαρκινικού παράγοντα και για την αγωγή δερματικών νόσων όπως η ψωρίαση καθώς και δερματικών καταστάσεων όπως οι ρυτίδες, το χαλαρό δέρμα, το ξηρό δέρμα και η ανεπαρκής έκκριση σμήγματος. Η ένωση αυτή έχει επίσης μικρή, αν όχι και μηδενική, ασβεσταιμική δράση και συνεπώς μπορεί να χρησιμοποιηθεί για την αγωγή ανοσολογικών διαταραχών σε ανθρώπους καθώς και της νεφρικής οστεοδυστροφίας.
CY20091100032T 2001-12-13 2009-01-14 (20s)-1 α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομοπρεγνακαλσιφερολη και οι χρησεις της CY1108686T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34113801P 2001-12-13 2001-12-13
US10/078,204 US6627622B2 (en) 2002-02-18 2002-02-18 (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
EP02794233A EP1453798B1 (en) 2001-12-13 2002-12-12 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Publications (1)

Publication Number Publication Date
CY1108686T1 true CY1108686T1 (el) 2014-04-09

Family

ID=26760229

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100032T CY1108686T1 (el) 2001-12-13 2009-01-14 (20s)-1 α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομοπρεγνακαλσιφερολη και οι χρησεις της

Country Status (17)

Country Link
EP (1) EP1453798B1 (el)
JP (1) JP4149928B2 (el)
KR (1) KR100631457B1 (el)
CN (1) CN1308303C (el)
AT (1) ATE411283T1 (el)
AU (1) AU2002359680B2 (el)
CA (1) CA2468833C (el)
CY (1) CY1108686T1 (el)
DE (1) DE60229430D1 (el)
DK (1) DK1453798T3 (el)
ES (1) ES2315426T3 (el)
HK (1) HK1077804A1 (el)
MX (1) MXPA04005652A (el)
NZ (1) NZ533424A (el)
PT (1) PT1453798E (el)
SI (1) SI1453798T1 (el)
WO (1) WO2003051828A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
EP1828113B1 (en) * 2004-11-22 2010-05-12 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
AU2005309818A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1-alpha-hydroxy-bishomopregnacalciferol
AU2005309820B2 (en) * 2004-11-22 2011-06-23 Wisconsin Alumni Research Foundation 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
MX2007013558A (es) 2005-05-03 2008-01-24 Wisconsin Alumni Res Found Compuestos de 19,26,27-trinor-1a,25-dihidroxivitamina d3.
NZ570814A (en) * 2006-04-06 2011-11-25 Wisconsin Alumni Res Found 2-methylene-1alpha-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
US7648973B2 (en) * 2006-04-06 2010-01-19 Wisconsin Alumni Research Foundation 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
EP2001841B1 (en) * 2006-04-06 2012-06-13 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
US20080171728A1 (en) * 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
WO2009111695A1 (en) * 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
JP6035331B2 (ja) * 2011-06-14 2016-11-30 ウイスコンシン アラムニ リサーチ ファンデーション ３−デスオキシ−２−メチレン−１９−ノル−ビタミンｄ類似体およびそれらの使用
WO2013012644A1 (en) * 2011-07-18 2013-01-24 Wisconsin Alumni I Research Foundation 2-methylene-20(21)-dehydro-19,24,25,26,27,-pentanor-vitamin d analogs
JP6114292B2 (ja) * 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用
JP6072811B2 (ja) * 2011-10-21 2017-02-01 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58473B1 (en) * 1985-04-23 1993-09-22 Wisconsin Alumni Res Found Seco-sterol compounds effective in inducing the differentiation of malignant cells
JPH05238937A (ja) * 1992-03-09 1993-09-17 Wisconsin Alumni Res Found 細胞分化誘発薬剤
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele

Also Published As

Publication number Publication date
KR100631457B1 (ko) 2006-10-11
PT1453798E (pt) 2009-01-23
NZ533424A (en) 2006-08-31
KR20040063949A (ko) 2004-07-14
ATE411283T1 (de) 2008-10-15
EP1453798A2 (en) 2004-09-08
JP4149928B2 (ja) 2008-09-17
CA2468833A1 (en) 2003-06-26
HK1077804A1 (en) 2006-02-24
EP1453798B1 (en) 2008-10-15
WO2003051828A2 (en) 2003-06-26
AU2002359680A1 (en) 2003-06-30
CN1308303C (zh) 2007-04-04
SI1453798T1 (sl) 2009-04-30
ES2315426T3 (es) 2009-04-01
WO2003051828A3 (en) 2003-09-12
CA2468833C (en) 2009-09-08
AU2002359680B2 (en) 2007-10-18
JP2005513066A (ja) 2005-05-12
MXPA04005652A (es) 2005-03-23
DE60229430D1 (de) 2008-11-27
DK1453798T3 (da) 2009-02-16
CN1620431A (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
CY1108686T1 (el) (20s)-1 α-υδροξυ-2-μεθυλενιο-19-νορ-δις-ομοπρεγνακαλσιφερολη και οι χρησεις της
ATE273709T1 (de) 1alpha-hydroxy-2-methylene-19-nor- homopregnacalciferol und seine therapeutische verwendungen
EP1482951B8 (en) 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
ATE467614T1 (de) 2-methylen-19,26,27-trinor-(20s)-1-alpha- hydroxyvitamin d3 and dessen verwendungen
WO2006057884A3 (en) 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
WO2006057899A3 (en) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
WO2006057901A3 (en) 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES
ATE472528T1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen
ATE552239T1 (de) 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga
WO2006057902A3 (en) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2009086439A3 (en) 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs